Quantcast

Latest Nebulizer Stories

2010-06-17 12:22:00

MONMOUTH JUNCTION, N.J., June 17 /PRNewswire/ -- Transave, Inc., today reported interim results from a multi-cycle Phase II open label clinical trial in cystic fibrosis (CF) patients on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation). The data indicated that ARIKACE, delivered once daily for 28 consecutive days followed by 56 days off-treatment for four cycles demonstrated statistically significant improvement in lung function that was sustained during the...

2010-05-24 09:00:00

BEIJING, May 24 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM), an emerging leader in the development, assembly, marketing and sale of medical products in China, announced today an exclusive distributor agreement for HEYER Medical's Cumulus ultrasonic nebulizer in China. Dehaier is authorized to distribute all models of this product. HEYER Cumulus is suitable for the treatment of respiratory tract conditions such as asthma, bronchitis, chronic respiratory...

2010-05-24 06:00:00

MONMOUTH JUNCTION, N.J., May 24 /PRNewswire/ -- Transave Inc. today announced that the United States Patent and Trademark Office has issued an important composition of matter patent (U.S. Patent No. 7,718,189) for liposomal aminoglycoside formulations including its lead compound, ARIKACE(TM) (liposomal amikacin for inhalation). The company expects that the patent will provide exclusivity for ARIKACE until October 1, 2026. "The issuance of this composition of matter patent significantly...

2010-05-17 07:00:00

SAN DIEGO, May 17 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today announced the presentation of data from its Phase 2b clinical trial with Aeroquin(TM) (a proprietary aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF) at the American Thoracic Society (ATS) Annual Meeting in New Orleans. Trial results demonstrated statistically significant improvements in bacterial load, respiratory function and time to need for anti-pseudomonal antibiotics (a measure of exacerbations)...

2010-03-01 09:00:00

MIDLOTHIAN, Va., March 1 /PRNewswire/ -- Today, PARI Respiratory Equipment launched their newest aerosol delivery system, the Vios. Paired with PARI's gold standard reusable nebulizers, Vios delivers fast treatments, small particle size, and high respirable drug dose to the lungs. Vios also features an extended warranty and Timestrip, an easy to use reminder for patients to replace their nebulizer every six months. "We are excited for physicians treating respiratory diseases to begin...

2010-02-23 10:22:00

MONTEREY, Calif., Feb. 23 /PRNewswire/ -- Altera, which uses eFlow Technology, was cleared to market today by the FDA as the first drug-specific nebulizer for use in the treatment of patients with cystic fibrosis and has been specifically developed to deliver Gilead Sciences' Cayston (aztreonam for inhalation solution) 75 mg. Cayston is a new inhaled antibiotic that received marketing approval from the U.S. Food and Drug Administration (FDA) yesterday as a treatment to improve respiratory...

2010-02-22 20:48:00

CF Foundation's $1 Million Investment Helped Drug Known as Cayston(R) Become a Reality BETHESDA, Md., Feb. 22 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration approved an important new inhaled antibiotic called Cayston® (aztreonam for inhalation solution) today for the treatment of cystic fibrosis. The drug was made possible by significant support from the Cystic Fibrosis Foundation, including a $1 million investment by a Foundation subsidiary to help...

2010-02-11 09:00:00

MONTEREY, Calif., Feb. 11 /PRNewswire/ -- PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging. "We are very pleased to...

2010-01-21 07:00:00

SAN DIEGO, Jan. 21 /PRNewswire/ -- Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today the closing of a $30 million tranched Series A financing. Investors participating include Canaan Partners, TPG Growth, Care Capital, and Mesa Verde Venture Partners. Concurrent with this financing, Elevation has added to its board of directors Brent Ahrens, General Partner at Canaan,...

2009-11-18 10:58:00

NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Pulmonary Drug Delivery Technologies - A Global Market Perspective http://www.reportlinker.com/p0164238/Pulmonary-Drug-Delivery-Technologies---A-Global-Market-Perspective.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire Until recent years, respiratory conditions such as asthma, chronic obstructive pulmonary, and emphysema disease...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related